240 related articles for article (PubMed ID: 36384590)
21. Neoantigens: promising targets for cancer therapy.
Xie N; Shen G; Gao W; Huang Z; Huang C; Fu L
Signal Transduct Target Ther; 2023 Jan; 8(1):9. PubMed ID: 36604431
[TBL] [Abstract][Full Text] [Related]
22. Identification of T Cell Receptors Targeting a Neoantigen Derived from Recurrently Mutated FGFR3.
Tate T; Matsumoto S; Nemoto K; Leisegang M; Nagayama S; Obama K; Nakamura Y; Kiyotani K
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831375
[TBL] [Abstract][Full Text] [Related]
23. TCR-engineered T cell therapy in solid tumors: State of the art and perspectives.
Baulu E; Gardet C; Chuvin N; Depil S
Sci Adv; 2023 Feb; 9(7):eadf3700. PubMed ID: 36791198
[TBL] [Abstract][Full Text] [Related]
24. Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T.
Liu Q; Li J; Zheng H; Yang S; Hua Y; Huang N; Kleeff J; Liao Q; Wu W
Mol Cancer; 2023 Feb; 22(1):28. PubMed ID: 36750830
[TBL] [Abstract][Full Text] [Related]
25. The landscape of T cell antigens for cancer immunotherapy.
Peri A; Salomon N; Wolf Y; Kreiter S; Diken M; Samuels Y
Nat Cancer; 2023 Jul; 4(7):937-954. PubMed ID: 37415076
[TBL] [Abstract][Full Text] [Related]
26. Targeting KRAS
Ai Q; Li F; Zou S; Zhang Z; Jin Y; Jiang L; Chen H; Deng X; Peng C; Mou N; Wen C; Shen B; Zhan Q
Front Immunol; 2023; 14():1161538. PubMed ID: 37287989
[TBL] [Abstract][Full Text] [Related]
27. Engineered T cell therapy for viral and non-viral epithelial cancers.
Norberg SM; Hinrichs CS
Cancer Cell; 2023 Jan; 41(1):58-69. PubMed ID: 36400016
[TBL] [Abstract][Full Text] [Related]
28. A microfluidics-enabled automated workflow of sample preparation for MS-based immunopeptidomics.
Li X; Pak HS; Huber F; Michaux J; Taillandier-Coindard M; Altimiras ER; Bassani-Sternberg M
Cell Rep Methods; 2023 Jun; 3(6):100479. PubMed ID: 37426762
[TBL] [Abstract][Full Text] [Related]
29. TP53 Alterations in Myelodysplastic Syndromes and Acute Myeloid Leukemia.
Rahmé R; Braun T; Manfredi JJ; Fenaux P
Biomedicines; 2023 Apr; 11(4):. PubMed ID: 37189770
[TBL] [Abstract][Full Text] [Related]
30. A perspective of immunotherapy for acute myeloid leukemia: Current advances and challenges.
Chen Y; Wang J; Zhang F; Liu P
Front Pharmacol; 2023; 14():1151032. PubMed ID: 37153761
[TBL] [Abstract][Full Text] [Related]
31. Dominant neoantigen verification in hepatocellular carcinoma by a single-plasmid system coexpressing patient HLA and antigen.
Chen P; Chen D; Bu D; Gao J; Qin W; Deng K; Ren L; She S; Xu W; Yang Y; Xie X; Liao W; Chen H
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37076248
[TBL] [Abstract][Full Text] [Related]
32. Novel CD19-specific γ/δ TCR-T cells in relapsed or refractory diffuse large B-cell lymphoma.
Li C; Zhou F; Wang J; Chang Q; Du M; Luo W; Zhang Y; Xu J; Tang L; Jiang H; Liu L; Kou H; Lu C; Liao D; Wu J; Wei Q; Ke S; Deng J; Liu C; Mei H; Hu Y
J Hematol Oncol; 2023 Jan; 16(1):5. PubMed ID: 36681817
[TBL] [Abstract][Full Text] [Related]
33. Tumor-Derived Antigenic Peptides as Potential Cancer Vaccines.
Sotirov S; Dimitrov I
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732150
[TBL] [Abstract][Full Text] [Related]
34. Enhanced cellular therapy: revolutionizing adoptive cellular therapy.
Xu MY; Zeng N; Liu CQ; Sun JX; An Y; Zhang SH; Xu JZ; Zhong XY; Ma SY; He HD; Hu J; Xia QD; Wang SG
Exp Hematol Oncol; 2024 Apr; 13(1):47. PubMed ID: 38664743
[TBL] [Abstract][Full Text] [Related]
35. Challenges and strategies associated with CAR-T cell therapy in blood malignancies.
Liu Z; Lei W; Wang H; Liu X; Fu R
Exp Hematol Oncol; 2024 Feb; 13(1):22. PubMed ID: 38402232
[TBL] [Abstract][Full Text] [Related]
36. Exploiting innate immunity for cancer immunotherapy.
Yi M; Li T; Niu M; Mei Q; Zhao B; Chu Q; Dai Z; Wu K
Mol Cancer; 2023 Nov; 22(1):187. PubMed ID: 38008741
[TBL] [Abstract][Full Text] [Related]
37. Multidisciplinary recommendations for the management of CAR-T recipients in the post-COVID-19 pandemic era.
Zhang T; Tian W; Wei S; Lu X; An J; He S; Zhao J; Gao Z; Li L; Lian K; Zhou Q; Zhang H; Wang L; Su L; Kang H; Niu T; Zhao A; Pan J; Cai Q; Xu Z; Chen W; Jing H; Li P; Zhao W; Cao Y; Mi J; Chen T; Chen Y; Zou P; Lukacs-Kornek V; Kurts C; Li J; Liu X; Mei Q; Zhang Y; Wei J
Exp Hematol Oncol; 2023 Jul; 12(1):66. PubMed ID: 37501090
[TBL] [Abstract][Full Text] [Related]
38. Detection of mutant antigen-specific T cell receptors against multiple myeloma for T cell engineering.
Okada M; Shimizu K; Nakazato H; Yamasaki S; Fujii SI
Mol Ther Methods Clin Dev; 2023 Jun; 29():541-555. PubMed ID: 37359417
[TBL] [Abstract][Full Text] [Related]
39. Neoantigen-specific TCR-T cell-based immunotherapy for acute myeloid leukemia.
Zhou W; Yu J; Li Y; Wang K
Exp Hematol Oncol; 2022 Nov; 11(1):100. PubMed ID: 36384590
[TBL] [Abstract][Full Text] [Related]
40. Discovery of U2AF1 neoantigens in myeloid neoplasms.
Biernacki MA; Lok J; Black RG; Foster KA; Cummings C; Woodward KB; Monahan T; Oehler VG; Stirewalt DL; Wu D; Rongvaux A; Deeg HJ; Bleakley M
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38164756
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
